KIT is an independent prognostic marker for pancreatic endocrine tumors: A finding derived from analysis of islet cell differentiation markers

American Journal of Surgical Pathology

Volumn 33, Issue 10, 2009, Pages 1562-1569

  Zhang, Lizhi ^a   Smyrk, Thomas C ^a   Oliveira, Andre M ^a   Lohse, Christine M ^a   Zhang, Shuya ^a   Johnson, Michele R ^a   Lloyd, Ricardo V ^a  

^a MAYO CLINIC   (United States)

Author keywords

CK19; KIT; Pancreatic endocrine tumor

Indexed keywords

CYTOKERATIN 19; KI 67 ANTIGEN; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX4; TRANSCRIPTION FACTOR PAX6; TRANSCRIPTION FACTOR PDX 1;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CLINICAL FEATURE; DISEASE MARKER; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MITOSIS; MULTIVARIATE ANALYSIS; PANCREAS ISLET CELL TUMOR; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; TUMOR VOLUME; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EYE PROTEINS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; KAPLAN-MEIERS ESTIMATE; KERATIN-19; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAIRED BOX TRANSCRIPTION FACTORS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRESSOR PROTEINS; STEM CELL FACTOR; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 70349678291     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181ac675b     Document Type: Article

References (36)

1. Ali A, Serra S, Asa SL, et al. The predictive value of CK19 and CD99 in pancreatic endocrine tumors. Am J Surg Pathol. 2006;30: 1588-1594.
2. Bouwens L, Lu WG, De Krijger R. Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia. 1997;40: 398-404.
3. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425:547-560.
4. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.
5. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and Genetics. Tumors of Endocrine Organs. Lyon: IARC Press; 2004:179.
6. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol. 2004;28:1145-1153.
7. Duensing A, Heinrich MC, Fletcher CD, et al. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest. 2004;22:106-116.
8. Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609-5615.
9. Goto A, Niki T, Terado Y, et al. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology. 2004;45:384-392.
10. Gupta P, Tewari M, Shukla HS. Gastrointestinal stromal tumor. Surg Oncol. 2008;17:129-138.
11. Hassan HT. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res. 2009;33: 5-10.
12. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642.
13. Hoei-Hansen CE, Kraggerud SM, Abeler VM, et al. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007;6:12.
14. Hong SM, Hwang I, Song DE, et al. Clinical and prognostic significances of nuclear and cytoplasmic KIT expressions in extrahepatic bile duct carcinomas. Mod Pathol. 2007;20:562-569.
15. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26:3403-3410.
16. La Rosa S, Rigoli E, Uccella S, et al. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology. 2007;50:597-606.
17. La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40:30-40.
18. Larsson LI. On the development of the islets of Langerhans. Microsc Res Tech. 1998;43:284-291.
19. Li J, Goodyer CG, Fellows F, et al. Stem cell factor/c-Kit interactions regulate human islet-epithelial cluster proliferation and differentiation. Int J Biochem Cell Biol. 2006;38:961-972.
20. Li J, Quirt J, Do HQ, et al. Expression of c-Kit receptor tyrosine kinase and effect on beta-cell development in the human fetal pancreas. Am J Physiol Endocrinol Metab. 2007;293:E475-E483.
21. Nio Y, Omori H, Hashimoto K, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res. 2005; 25:3523-3529.
22. Ohike N, Morohoshi T. Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation. Pathol Int. 2001;51:770-777.
23. Oliver-Krasinski JM, Stoffers DA. On the origin of the beta cell. Genes Dev. 2008;22:1998-2021.
24. Piper K, Brickwood S, Turnpenny LW, et al. Beta cell differentiation during early human pancreas development. J Endocrinol. 2004;181:11-23.
25. Rahman A, Maitra A, Ashfaq R, et al. Loss of p27 nuclear expression in a prognostically favorable subset of well-differentiated pancreatic endocrine neoplasms. Am J Clin Pathol. 2003;120: 685-690.
26. Rindi G, de Herder WW, O'Toole D, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it. Neuroendocrinology. 2006;84:155-157.
27. Riss D, Jin L, Qian X, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res. 2003;63:2251-2255.
28. Salto-Tellez M, Nga ME, Han HC, et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumours. Br J Cancer. 2007;96:776-782.
29. Sammarco I, Capurso G, Coppola L, et al. Expression of the protooncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients. Int J Colorectal Dis. 2004;19:545-553.
30. Schindl M, Kaczirek K, Kaserer K, et al. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg. 2000;24:1312-1318.
31. Schmandt RE, Broaddus R, Lu KH, et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer. 2003;98:758-764.
32. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol. 2007;31:1677-1682.
33. Soria B. In-vitro differentiation of pancreatic beta-cells. Differentiation. 2001;68:205-219.
34. Tsuda H, Tani Y, Weisenberger J, et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated- type breast carcinomas with "stem-cell-like" features. Cancer Sci. 2005;96:333-339.
35. Yao JC, Zhang JX, Rashid A, et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007;13: 234-240.
36. Yasuda A, Sawai H, Takahashi H, et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer. 2006;5:46.